Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Immunization with Human Papillomavirus 16 L1+E2 Chimeric Capsomers Elicits Cellular Immune Response and Antitumor Activity in a Mouse Model.

López-Toledo G, Schädlich L, Alonso-Castro ÁJ, Monroy-García A, García-Rocha R, Guido MC, Gissmann L, García-Carrancá A.

Viral Immunol. 2016 Jun;29(5):276-87. doi: 10.1089/vim.2015.0080. Epub 2016 Apr 8.

PMID:
27058179
2.

Evaluation of specific humoral and cellular immune responses against the major capsid L1 protein of cutaneous wart-associated alpha-Papillomaviruses in solid organ transplant recipients.

Gaiser MR, Textor S, Senger T, Schädlich L, Waterboer T, Kaufmann AM, Süsal C, Pawlita M, Enk AH, Gissmann L, Lonsdorf AS.

J Dermatol Sci. 2015 Jan;77(1):37-45. doi: 10.1016/j.jdermsci.2014.11.002. Epub 2014 Nov 18.

PMID:
25439730
3.

Tumor prevention in HPV8 transgenic mice by HPV8-E6 DNA vaccination.

Marcuzzi GP, Awerkiew S, Hufbauer M, Schädlich L, Gissmann L, Eming S, Pfister H.

Med Microbiol Immunol. 2014 Jun;203(3):155-63. doi: 10.1007/s00430-014-0327-4. Epub 2014 Jan 21.

PMID:
24446083
4.

Human papillomavirus-specific immune therapy: failure and hope.

Nieto K, Gissmann L, Schädlich L.

Antivir Ther. 2010;15(7):951-7. doi: 10.3851/IMP1665. Review.

PMID:
21041909
5.

Virus-like particles and capsomeres are potent vaccines against cutaneous alpha HPVs.

Senger T, Schädlich L, Textor S, Klein C, Michael KM, Buck CB, Gissmann L.

Vaccine. 2010 Feb 10;28(6):1583-93. doi: 10.1016/j.vaccine.2009.11.048. Epub 2009 Dec 8.

PMID:
20003923
6.

Identification of B-cell epitopes on virus-like particles of cutaneous alpha-human papillomaviruses.

Senger T, Becker MR, Schädlich L, Waterboer T, Gissmann L.

J Virol. 2009 Dec;83(24):12692-701. doi: 10.1128/JVI.01582-09. Epub 2009 Sep 30.

7.

Analysis of modified human papillomavirus type 16 L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity.

Schädlich L, Senger T, Gerlach B, Mücke N, Klein C, Bravo IG, Müller M, Gissmann L.

J Virol. 2009 Aug;83(15):7690-705. doi: 10.1128/JVI.02588-08. Epub 2009 May 20.

8.

Enhanced papillomavirus-like particle production in insect cells.

Senger T, Schädlich L, Gissmann L, Müller M.

Virology. 2009 Jun 5;388(2):344-53. doi: 10.1016/j.virol.2009.04.004. Epub 2009 May 1.

9.

Refining HPV 16 L1 purification from E. coli: reducing endotoxin contaminations and their impact on immunogenicity.

Schädlich L, Senger T, Kirschning CJ, Müller M, Gissmann L.

Vaccine. 2009 Mar 4;27(10):1511-22. doi: 10.1016/j.vaccine.2009.01.014. Epub 2009 Jan 25.

PMID:
19174177
10.

A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response.

Thönes N, Herreiner A, Schädlich L, Piuko K, Müller M.

J Virol. 2008 Jun;82(11):5472-85. doi: 10.1128/JVI.02482-07. Epub 2008 Apr 2.

11.

Development of a novel recombinant encapsidated RNA particle: evaluation as an internal control for diagnostic RT-PCR.

King DP, Montague N, Ebert K, Reid SM, Dukes JP, Schädlich L, Belsham GJ, Lomonossoff GP.

J Virol Methods. 2007 Dec;146(1-2):218-25. Epub 2007 Aug 28.

PMID:
17727966

Supplemental Content

Loading ...
Support Center